COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,226 Articles (22,733 medRxiv, 8,493 bioRxiv)

Most recent first Previous |  Page 286: Articles 2851-2860  | Next

Retrospective analysis of Covid-19 hospitalization modelling scenarios which guided policy response in France
Langevin, M., Starck, T.
10.1101/2023.12.16.23300086 — Posted: 2023-12-17
COVID-19 vaccine uptake and acceptability during the second phase of vaccine rollout: a community-based survey among household heads in Zamfara state, Nigeria, 2021
Ahmad, S. I., Aliyu, H., Usman, R., Abubakar, A. T., Abdullahi, M. M., Suleiman, B. A., Balogun, M. S., Olorukooba, A., Umeokonkwo, C. D., Maiyaki, A., Sani, M., Yisa, M., Zubair, I. H., Hastings, C. O., Jatau, T. D., Sabitu, K.
10.1101/2023.12.14.23299963 — Posted: 2023-12-15
PVT in patients presenting with post-acute sequelae of COVID-19
Chakrabarti, S., Krishnan, K., Galioto, R.
10.1101/2023.12.14.23299928 — Posted: 2023-12-15
Diagnostic Accuracy of the Abbot BinaxNOW COVID-19 Antigen Card Test, Puerto Rico
Madewell, Z. J., Major, C. G., Graff, N., Adams, C., Rodriguez, D. M., Morales, T., Medina Lopes, N. A., Tosado, R., Sanchez-Gonzalez, L., Perez-Padilla, J., Volkman, H. R., Bertran, J., Sainz, D., Munoz-Jordan, J., Santiago, G. A., Lorenzi, O., Rivera-Amill, V., Rolfes, M. A., Paz-Bailey, G., Adams, L. E., Wong, J. M., PRESCA Study Team
10.1101/2023.12.14.23299967 — Posted: 2023-12-15
Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization
Arghal, R., Rubin, H., Saeedi Bidokhti, S., Sarkar, S.
10.1101/2023.12.10.23299100 — Posted: 2023-12-15
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
Olmedillas, E., Rajamanickam, R. R., Diaz, R., Sosa Batiz, F. A., Zandonatti, M. A., Harkins, S. S., Shresta, S., Hastie, K., Saphire, E. O.
10.1101/2023.12.14.571764 — Posted: 2023-12-15
SARS-CoV-2 and other coronaviruses in rats, Berlin, Germany, 2023
Wernike, K., Mehl, C., Aebischer, A., Heising, M., Ulrich, R. G., Beer, M.
10.1101/2023.12.15.571826 — Posted: 2023-12-15
Metacell-based differential expression analysis identifies cell type specific temporal gene response programs in COVID-19 patient PBMCs
O'Leary, K., Zheng, D.
10.1101/2023.12.14.571774 — Posted: 2023-12-15
Asymptomatic SARS-CoV-2 infections tend to occur less frequently in developed nations
Chowdhury, S., Tiwari, A., James, A., Chatterjee, B., Dixit, N. M.
10.1101/2023.12.14.23299954 — Posted: 2023-12-14
A distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia
Markov, N. S., Ren, Z., Senkow, K. J., Grant, R. A., Gao, C. A., Malsin, E. S., Sichizya, L., Kihshen, H., Helmin, K. A., Jovisic, M., Arnold, J. M., Perez-Leonor, X. G., Abdala-Valencia, H., Swaminathan, S., Nwaezeapu, J., Kang, M., Rasmussen, L., Ozer, E. A., Lorenzo-Redondo, R., Hultquist, J. F., Simons, L., Rios-Guzman, E., Misharin, A. V., Wunderink, R. G., Budinger, G. S., Singer, B. D., Morales-Nebreda, L., The NU SCRIPT Investigators
10.1101/2023.12.13.571479 — Posted: 2023-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).